Trials / Withdrawn
WithdrawnNCT01507532
Pharmacokinetic Assessment of Ceftazidime in Intermittent Hemodialysis Patients
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Midwestern University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Ceftazidime is a broad spectrum cephalosporin with high activity against a variety of Gram-negative pathogens, including Pseudomonas aeruginosa. An open-label study of intravenous ceftazidime pharmacokinetics will be performed in patients undergoing intermittent hemodialysis at Northwestern Memorial Hospital to determine the clearance of ceftazidime in high flux hemodialysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | pharmacokinetic monitoring | pharmacokinetic monitoring |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2016-01-01
- Completion
- 2016-01-01
- First posted
- 2012-01-11
- Last updated
- 2018-03-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01507532. Inclusion in this directory is not an endorsement.